Literature DB >> 23668469

Rift Valley fever among children and adolescents in southwestern Saudi Arabia.

Tarik A Al Azraqi1, Awad A El Mekki, Ahmed A Mahfouz.   

Abstract

PURPOSE: Rift Valley fever (RVF) virus has expanded its geographical range, reaching Asia in 2000. This work investigated RVF seroprevalence among children born after the 2000-2001 outbreak in Saudi Arabia and compared it with the seroprevalence of adolescents born before the outbreak.
DESIGN: In a seroepidemiological study in southwestern Saudi Arabia (Jazan, Aseer, and Al-Qunfuda), a random sample of 389 children and adolescents was investigated. Data were collected regarding the subjects' sociodemographic status, housing conditions, and animal contact. Blood samples were collected and tested for RVF-specific IgG and IgM.
RESULTS: None of the study samples were found to be seropositive for anti-RVF virus IgM. None of the study subjects aged 1-8 years (born after the outbreak) were positive for RVF-specific IgG. In contrast, 14 subjects (4.8%) aged 9-19 years (born before the outbreak) were positive for RVF-specific IgG. Among adolescents in our study, 4.9% were positive for anti-RVF IgG. This study showed that among adolescents, a history of contact with aborted animals (aOR=13.361, 95% CI=5.091-35.072) and transporting aborted animals (aOR=18.861, 95% CI=11.125-31.622) were significant risk factors.
CONCLUSIONS: Despite the low virus activity recently reported among animals, neither clinically apparent RVF infections nor outbreaks among humans have been documented, indicating that the control measures taken by the Ministry of Agriculture and Ministry of Health are effective.
Copyright © 2013 King Saud Bin Abdulaziz University for Health Sciences. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23668469     DOI: 10.1016/j.jiph.2012.11.011

Source DB:  PubMed          Journal:  J Infect Public Health        ISSN: 1876-0341            Impact factor:   3.718


  4 in total

1.  Elevated antibodies against Rift Valley fever virus among humans with exposure to ruminants in Saudi Arabia.

Authors:  Ziad A Memish; Malak A Masri; Benjamin D Anderson; Gary L Heil; Hunter R Merrill; Salah U Khan; Ahmad Alsahly; Gregory C Gray
Journal:  Am J Trop Med Hyg       Date:  2015-02-02       Impact factor: 2.345

2.  Cytokine response in mouse bone marrow derived macrophages after infection with pathogenic and non-pathogenic Rift Valley fever virus.

Authors:  Kimberly K Roberts; Terence E Hill; Melissa N Davis; Michael R Holbrook; Alexander N Freiberg
Journal:  J Gen Virol       Date:  2015-03-10       Impact factor: 3.891

3.  Combination Kinase Inhibitor Treatment Suppresses Rift Valley Fever Virus Replication.

Authors:  Todd M Bell; Virginia Espina; Lindsay Lundberg; Chelsea Pinkham; Ashwini Brahms; Brian D Carey; Shih-Chao Lin; Bibha Dahal; Caitlin Woodson; Cynthia de la Fuente; Lance A Liotta; Charles L Bailey; Kylene Kehn-Hall
Journal:  Viruses       Date:  2018-04-13       Impact factor: 5.048

Review 4.  The challenging management of Rift Valley Fever in humans: literature review of the clinical disease and algorithm proposal.

Authors:  Emilie Javelle; Alexandre Lesueur; Vincent Pommier de Santi; Franck de Laval; Thibault Lefebvre; Guillaume Holweck; Guillaume André Durand; Isabelle Leparc-Goffart; Gaëtan Texier; Fabrice Simon
Journal:  Ann Clin Microbiol Antimicrob       Date:  2020-01-22       Impact factor: 3.944

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.